ANVISA guidance [Regulatives / Guidelines]

posted by Dr_Dan  – Germany, 2010-04-01 17:34 (5306 d 05:18 ago) – Posting: # 4996
Views: 3,686

Dear Priyanka_S
If you realize, that samples are missing you have to decide before you start your bioanalysis if you want to include this subject into statistical analysis or not. If you do not want to include this subject into statistical analysis (because missing samples occurred around tmax) you do not need to measure the samples (then you are on the safe side). If this subject experienced an AE possibly related with the study medication you have to measure the samples for safety reasons. In this case you have to document clearly that this subject will not be included into statistical analysis.
It is always a disadvantage to exclude a subject, unless you have pre-specified procedures in your study protocol, otherwise the regulatory authority could always ask to present the evaluation with and without that subject.
I hope this helps
Dan

Kind regards and have a nice day
Dr_Dan

Complete thread:

UA Flag
Activity
 Admin contact
23,249 posts in 4,885 threads, 1,652 registered users;
67 visitors (0 registered, 67 guests [including 9 identified bots]).
Forum time: 22:52 CEST (Europe/Vienna)

The rise of biometry in this 20th century,
like that of geometry in the 3rd century before Christ,
seems to mark out one of the great ages or critical periods
in the advance of the human understanding.    R.A. Fisher

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5